Albireo Pharma Inc (NASDAQ:ALBO)
| 24.51 Delayed Data As of 4:00pm ET |  -0.41 / -1.65%Today’s Change | 16.13 Today|||52-Week Range 38.69 | -3.58% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $370.7M |
Company Description
Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
Contact Information
Albireo Pharma, Inc. 10 Post Office Square Boston Massachusetts 02109 |
Employees
Shareholders
| Other institutional | 36.22% |
| Mutual fund holders | 35.97% |
| Individual stakeholders | 29.00% |
Top Executives
| There are no executives to display. |
